Hemay005 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
56	Behcet disease	1
271	Ankylosing spondylitis	1

56. Behcet disease

---

Clinical trials : 81 /  Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04609397 (ClinicalTrials.gov)	November 30, 2020	19/10/2020	A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease	A Phase ? Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease	Behçet Disease	Drug: Hemay005;Other: Placebo	Tianjin Hemay Pharmaceutical Co., Ltd	NULL	Terminated	18 Years	75 Years	All	89	Phase 2	China

271. Ankylosing spondylitis

---

Clinical trials : 574 /  Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05407246 (ClinicalTrials.gov)	June 24, 2022	30/5/2022	Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing Spondylitis	Active Ankylosing Spondylitis	Drug: Hemay005	Tianjin Hemay Pharmaceutical Co., Ltd	NULL	Not yet recruiting	18 Years	65 Years	All	90	Phase 2	China